Retatrutide 20mg

The 20mg vial contains twice the active compound at identical 99.4% HPLC purity. It is the better-value choice for: researchers who have validated Retatrutide in a 10mg protocol and are moving to an extended study; larger in-vivo cohorts requiring multiple animals dosed from a single vial; protocols with a longer dosing duration per vial; or researchers who want to reduce the frequency of reorders. The [10mg format](/products/retatrutide-10mg) remains the starting point for researchers new to the compound. Both formats are from the same GMP-certified source and independently batch-verified. Not for human consumption — for research use only.

Retatrutide simultaneously agonises three G-protein coupled receptors: GLP-1R (glucagon-like peptide-1 receptor) — suppresses appetite via hypothalamic and vagal pathways and modulates insulin secretion; GIPR (glucose-dependent insulinotropic polypeptide receptor) — enhances postprandial insulin response and fat cell metabolism; GCGR (glucagon receptor) — stimulates hepatic fuel mobilisation and thermogenesis, increasing energy expenditure. The glucagon component is key: GLP-1R co-activation suppresses the hyperglycaemic risk of glucagon, allowing the thermogenic and lipolytic aspects to be studied cleanly. This triple mechanism is absent from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP only). Not for human consumption — for research use only.

Phase 2 data from the TRIUMPH programme (Eli Lilly) showed mean body weight reductions of up to 24.2% over 48 weeks at the highest dose cohort — surpassing both semaglutide (~15% at 2.4mg) and tirzepatide (~22.5% at 15mg) in comparable timeframes. Secondary endpoints included improvements in waist circumference, systolic blood pressure, fasting lipids, and glycaemic markers. The Phase 2 data positioned Retatrutide as the most efficacious GLP-1 class compound studied to date by weight reduction magnitude. These are clinical research findings; our Retatrutide 20mg is supplied for preclinical research use only. Not for human consumption — for research use only.

Reconstitution: Draw 2–4mL of bacteriostatic water into a clean 31G insulin syringe. Inject slowly down the inside glass wall of the Retatrutide 20mg vial. Gently swirl until fully dissolved — do not shake or vortex. The solution should be clear and colourless. Label with compound, concentration, and date. Example concentrations: 2mL BAC water = 10mg/mL; 4mL = 5mg/mL. Storage: Lyophilised — store at −20°C for up to 12–24 months. Reconstituted — store at 2–8°C and use within 28 days. Avoid freeze-thaw cycling of the reconstituted solution. Our [BAC Water 10mL](/products/bac-water-10ml) and [Insulin Needles 31G](/products/insulin-needles-31g) are available for a complete setup.

Retatrutide is legal to purchase in Australia for legitimate laboratory research purposes. It is not listed as a scheduled substance under the Therapeutic Goods Act or the Poisons Standard when sold for research use only. Purchasers must be 18+ and confirm research-only use. It is not approved for human consumption or therapeutic use by the TGA. Our Retatrutide 20mg is independently verified at 99.4% HPLC purity with full COA documentation.

Peptide Warehouse dispatches Retatrutide 20mg nationwide via Australia Post with full tracking from our Melbourne warehouse. Orders placed before 11PM AEST dispatch the next business day. Standard Post (2–6 business days) $9.99; Express Post (1–3 business days) $15.99. Free shipping on orders over $199 AUD. Discreet plain packaging. Also available in the [10mg format](/products/retatrutide-10mg) and as part of the [Retatrutide Research Bundle](/products/retatrutide-bundle).

Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist only. Tirzepatide (Mounjaro) adds GIP receptor agonism to the GLP-1 mechanism. Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination — making it a triple agonist. The glucagon component drives hepatic fuel mobilisation and thermogenesis that single or dual agonists do not produce. Phase 2 data showed greater body weight reduction than either predecessor. Each compound has a distinct receptor profile and is not interchangeable as a research tool. Not for human consumption — for research use only.